US Markets

Eli Lilly's migraine treatment wins U.S. FDA approval

Publisher
Reuters
Published
Credit: REUTERS/VINCENT KESSLER

The U.S. Food and Drug Administration said on Friday it had approved Eli Lilly and Co's migraine drug, Reyvow.

Oct 11 (Reuters) - The U.S. Food and Drug Administration said on Friday it had approved Eli Lilly and Co's LLY.N migraine drug, Reyvow.

The drug, formerly called lasmiditan, has been approved to treat acute migraine with or without aura, a sensory phenomenon or visual disturbance, in adults.

(Reporting by Shivani Singh; Editing by Shinjini Ganguli)

((ShivaniSingh1@thomsonreuters.com;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

See more videos

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More

Explore US Markets

Explore

Most Popular